Tarsus Pharmaceuticals Enters Material Definitive Agreement
Ticker: TARS · Form: 8-K · Filed: Mar 13, 2025 · CIK: 1819790
| Field | Detail |
|---|---|
| Company | Tarsus Pharmaceuticals, Inc. (TARS) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
Tarsus Pharma signed a big deal, filing an 8-K on March 12, 2025.
AI Summary
Tarsus Pharmaceuticals, Inc. announced on March 12, 2025, that it has entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this Form 8-K filing. Specific details of the agreement and financial information were not provided in the excerpt.
Why It Matters
This filing indicates a significant new agreement for Tarsus Pharmaceuticals, which could impact its business operations and financial future.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which often involves significant financial commitments or strategic shifts, but lacks specific details to fully assess the risk.
Key Players & Entities
- Tarsus Pharmaceuticals, Inc. (company) — Registrant
- March 12, 2025 (date) — Date of earliest event reported
- 15440 Laguna Canyon Road, Suite 160 (address) — Principal executive offices
- Irvine, CA 92618 (address) — Principal executive offices
- (949) 418-1801 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Tarsus Pharmaceuticals?
The filing states that Tarsus Pharmaceuticals, Inc. entered into a material definitive agreement on March 12, 2025, but the specific details of this agreement are not disclosed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 12, 2025.
What is Tarsus Pharmaceuticals' principal executive office address?
Tarsus Pharmaceuticals' principal executive offices are located at 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (949) 418-1801.
What is the SIC code for Tarsus Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Tarsus Pharmaceuticals is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 13, 2025 regarding Tarsus Pharmaceuticals, Inc. (TARS).